Advertisement


Paul E. Goss, MD, PhD, on Postmenopausal Early-Stage Breast Cancer: Extending Letrozole Treatment

2016 ASCO Annual Meeting

Advertisement

Paul E. Goss, MD, PhD, of Massachusetts General Hospital Cancer Center and Harvard Medical School, discusses disease-free survival results from a study extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen (Abstract LBA1).



Related Videos

Bladder Cancer

Arjun Vasant Balar, MD, on Urothelial Carcinoma: Analysis of the IMvigor210 Cohort 1

Arjun Vasant Balar, MD, of the Perlmutter Cancer Center at NYU Langone Medical Center, discusses findings on atezolizumab as first-line therapy in cisplatin-ineligible locally advanced/metastatic disease (Abstract LBA4500).

Gynecologic Cancers

Eric Roeland, MD, and Linda Van Le, MD, on Gynecologic Cancers: Managing Menopausal Symptoms in Survivors

Eric Roeland, MD, of the University of California, San Diego, and Linda Van Le, MD, of the University of North Carolina discuss ways to manage symptoms that affect up to 80% of postmenopausal women, diminishing their quality of life.

Prostate Cancer

A. Oliver Sartor, MD, and Celestia S. Higano, MD, on Findings of the FIRSTANA Trial in Prostate Cancer

A. Oliver Sartor, MD, of Tulane University, and Celestia S. Higano, MD, of the University of Washington, discuss findings from this phase III study on cabazitaxel vs docetaxel in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (Abstract 5006).

Multiple Myeloma

Antonio Palumbo, MD, on Multiple Myeloma: Results From the CASTOR Trial

Antonio Palumbo, MD, of the University of Torino, discusses this phase III study of daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (Abstract LBA4).

Colorectal Cancer

Michael J. Overman, MD, and John Marshall, MD, on Metastatic Colorectal Cancer: Interim Results of the CheckMate 142 Trial

Michael J. Overman, MD, of the University of Texas MD Anderson Cancer Center, and John Marshall, MD, of Georgetown University Lombardi Comprehensive Cancer Center, discuss interim findings on nivolumab with or without ipilimumab in the treatment of patients with metastatic colorectal cancer with and without high microsatellite instability (Abstract 3501).

Advertisement

Advertisement




Advertisement